Harmony Biosciences Holdings, Inc. (HRMY)
Harmony Biosciences Holdings, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Plymouth Meeting, PA, US. The stock last traded at $42.86, up 3.90% on the session, giving a market capitalisation of $2.48B. On trailing twelve-month figures it carries a trailing P/E of 13.69, a net margin of 18.9%. Its beta of 0.91 implies it has historically moved less than the broad market.
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical firm dedicated to developing and marketing therapies for individuals in the United States who suffer from rare neurological conditions. Their flagship product, WAKIX, is a prescription medication designed to treat excessive daytime sleepiness in adult patients diagnosed with narcolepsy. The company, which was founded in 2017, was formerly known as Harmony Biosciences II, Inc. before adopting its current name in February 2020. Harmony Biosciences Holdings, Inc. operates out of Plymouth Meeting, Pennsylvania.
Harmony Biosciences Holdings, Inc. is most often compared with the following Healthcare names: